tiprankstipranks
Biorestorative Therapies, Inc. (BRTX)
NASDAQ:BRTX
US Market
BRTX
BioRestorative Therapies
RESEARCH TOOLSreports
Want to see BRTX full AI Analyst Report?

BioRestorative Therapies (BRTX) Earnings Dates, Call Summary & Reports

312 Followers

Earnings Data

Report Date
Aug 18, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.13
Last Year’s EPS
-0.3
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.
Company Guidance
In the third quarter of 2025, BioRestorative Therapies reported a mixed financial performance, with revenues significantly declining to approximately $11,800 from $233,600 in the same period of 2024, primarily due to timing in the biocosmeceutical revenue stream. The company reported a loss from operations of $3.7 million, up from $2.3 million in the previous year, and a net loss of $3 million or $0.33 per share, compared to a net loss of $1 million or $0.13 per share in 2024. Despite these financial challenges, BioRestorative Therapies ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities, excluding $1.1 million from recent financing. On the clinical front, the company is advancing its Phase II BRTX-100 study for chronic lumbar disc disease, with enrollment nearing completion and a potential Type B FDA meeting anticipated. The company also highlighted substantial progress in its ThermoStem program targeting obesity, while continuing discussions for a potential licensing agreement. The biocosmeceuticals business shows promise, with strategic leadership changes and a focus on expanding distribution channels, although revenue guidance remains uncertain.
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
ThermoStem Patent Milestone
The Japanese Patent Office issued a notice of allowance for BioRestorative Therapies' ThermoStem platform, providing broad protection terms for allogeneic, off-the-shelf brown adipose-derived stem cell technology.
Strengthening Commercial Infrastructure
BioRestorative Therapies has rebuilt and strengthened its commercial infrastructure, including supply chain, sales coverage, and distribution, with the appointment of Crystal Romano as Global Head of Commercial Operations.
Recent Financing Success
The company closed a fully subscribed financing priced above market, strengthening the balance sheet with gross proceeds of approximately $1.1 million.

BioRestorative Therapies (BRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

BRTX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 18, 2026
2026 (Q2)
-0.13 / -
-0.3―――
May 20, 2026
2026 (Q1)
-0.20 / -0.20
-0.6468.75% (+0.44)――
Mar 26, 2026
2025 (Q4)
-0.37 / -0.33
-0.2-65.00% (-0.13)――
Nov 12, 2025
2025 (Q3)
-0.36 / -0.33
-0.13-153.85% (-0.20)―
Aug 12, 2025
2025 (Q2)
-0.37 / -0.30
-0.540.00% (+0.20)―
May 14, 2025
2025 (Q1)
-0.33 / -0.64
-0.33-93.94% (-0.31)―
Mar 27, 2025
2024 (Q4)
-0.34 / -0.20
-0.666.67% (+0.40)―
Nov 12, 2024
2024 (Q3)
-0.43 / -0.13
-0.6479.69% (+0.51)―
Aug 13, 2024
2024 (Q2)
-0.57 / -0.50
-0.7735.06% (+0.27)――
May 14, 2024
2024 (Q1)
-0.52 / -0.33
-1.5378.43% (+1.20)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BRTX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 20, 2026
$0.18$0.17-7.65%
Mar 26, 2026
$0.31$0.30-4.52%
Nov 12, 2025
$1.38$1.25-9.42%
Aug 12, 2025
$1.47$1.50+2.04%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biorestorative Therapies, Inc. (BRTX) report earnings?
Biorestorative Therapies, Inc. (BRTX) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
    What is Biorestorative Therapies, Inc. (BRTX) earnings time?
    Biorestorative Therapies, Inc. (BRTX) earnings time is at Aug 18, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BRTX EPS forecast?
          BRTX EPS forecast for the fiscal quarter 2026 (Q2) is -0.13.